In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Targeting macrophage metabolism improves atherosclerosis outcome

Commented by Jeroen Baardman, Sanne G. S. Verberk, Menno P. J. de Winther & Jan Van den Bossche

Atherosclerosis, Cerebrovascular Diseases, Aneurysm, Restenosis
Vascular Diseases

Given the prominent role of macrophages in the progression of atherosclerosis, modulating their responses is considered as a promising strategy to treat atherosclerosis. Recent literature revealed an important role for ATP citrate lyase (Acly) in translating metabolic changes into altered macrophage phenotype and function.
Serving as a link between carbohydrate and lipid metabolism makes Acly a promising target to lower low-density lipoprotein (LDL) cholesterol levels and to reduce cardiovascular risk. Bempedoic acid is a competitive Acly inhibitor that is specifically activated in hepatocytes where it upregulates LDL receptor. Although promising data from clinical trials highlight that hepatic Acly inhibition reduces LDL cholesterol levels in hypercholesterolemic patients, the tools to study this key metabolic hub in macrophages in vivo remained absent.

To tackle this important question, we generated a new genetic knockout mouse model that specifically lacks Acly in macrophages and found that Acly deficiency in myeloid cells induces a stable plaque phenotype. The favorable plaque phenotype was linked to deregulated fatty acid and cholesterol biosynthesis and reduced liver X receptor activation within the macrophages. This resulted in macrophage apoptosis, along with more efficient efferocytosis and increased clearance of apoptotic cells. As such, we showed that targeting macrophage Acly improves atherosclerosis outcome in mice and can serve as a promising therapeutic target to stabilize atherosclerotic plaques.

Potential relevance for the clinic is supported by the observation that Acly is activated in inflammatory macrophages and in unstable human atherosclerotic plaques. An important next translational step is to test whether bempedoic acid or other Acly inhibitors also yield beneficial macrophage and plaque phenotypes in cardiovascular patients.


  • Macrophages in atherosclerosis: a dynamic balance. Moore KJ, Sheedy FJ, Fisher EA. Nat Rev Immunol. 2013 Oct;13(10):709-21.
  • Macrophage Phenotype and Function in Different Stages of Atherosclerosis. Tabas I, Bornfeldt KE. Circ Res. 2016 Feb 19;118(4):653-67.
  • Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the Europea Society of Cardiology. Ketelhuth DFJ, Lutgens E, Bäck M, Binder CJ, Van den Bossche J, Daniel C, Dumitriu IE, Hoefer I, Libby P, O'Neill L, Weber C, Evans PC. Cardiovasc Res. 2019 Jul 1;115(9):1385-1392.

Notes to editor

Baardman J, Verberk SGS, van der Velden S, Gijbels MJJ, van Roomen CPPA, Sluimer JC, Broos JY, Griffith GR, Prange KHM, van Weeghel M, Lakbir S, Molenaar D, Meinster E, Neele AE, Kooij G, de Vries HE, Lutgens E, Wellen KE, de Winther MPJ, Van den Bossche J. Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques. Nat Commun. 2020 Dec 8;11(1):6296.


The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.

Contact us

ESC Working Group on Atherosclerosis & Vascular Biology

European Society of Cardiology

European Heart House
Les Templiers
2035 Route des Colles
CS 80179 Biot

06903, Sophia Antipolis, FR

Tel: +